Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2016 16:36 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection

SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer...
January 06, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Biotech Showcase 2016

SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the...
December 07, 2015 06:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation

Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening...
December 03, 2015 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference

SAN DIEGO, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment...
November 05, 2015 09:05 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015

SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment...
November 05, 2015 09:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting

First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and...
November 03, 2015 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Third Quarter 2015 Financial Results

Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and...
October 29, 2015 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015

SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment...
October 28, 2015 08:30 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions

SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment...
October 12, 2015 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Leadership Transition

Scott Wolchko, a Fate Founder, to Succeed Christian Weyer as President and CEO Effective December 1, 2015 Additional Leadership Changes Enhance Fate Executive Team SAN DIEGO, Oct. 12, 2015...